United Kingdom · Series C startup
Funding summaryUpdated 26 Oct 2026
$442Mraised across 6 rounds since 2021, from 7 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Novo HoldingsLead
Forbion Capital PartnersLead
Google Ventures
Janus Henderson Investors
Oxford Science Enterprises
British Business Bank
Northpond Ventures
Sanofi Ventures
Syncona
University of Oxford
Jefferson Life SciencesReported by Jefferson Life Sciences and 1 other
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
OMass Therapeutics filed 5 raises, $127M in all. Filings say how much was sold and to how many investors; they never name the investors.
From OMass Therapeutics's own website: 3 founders, 14 on the team.
AdvisersProfessor Dame Carol Robinson
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Google VenturesOxford Science EnterprisesNorthpond VenturesNovo HoldingsLForbion Capital PartnersLBain Capital Life SciencesLJanus Henderson InvestorsBritish Business Bank
SanofiSV Health InvestorsMissing a round, or an investor who was in one? Tell us.
OMass Therapeutics's investors include Google Ventures, Oxford Science Enterprises, Northpond Ventures, Novo Holdings and Forbion Capital Partners, and 9 more on record. Novo Holdings led its latest round.
OMass Therapeutics has raised $442M across 6 rounds since 2021.
OMass Therapeutics's most recent round was a Series C of $310M in Oct 2026, led by Novo Holdings.
Its most recent round, $310M in Oct 2026, is also its largest on record.
OMass Therapeutics's first round on record, in May 2023, was backed by Google Ventures, Oxford Science Enterprises and Sanofi and 1 others.
OMass Therapeutics's latest named round is a Series C, in Oct 2026.
OMass Therapeutics is based in the United Kingdom.
Novo Holdings led the Series C in 2026.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United Kingdom · 
